Viking Therapeutics Inc (VKTX)

NASD · Healthcare · Biotechnology · USA

Viking Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. The company is advancing VK2735, a dual agonist of GLP-1 and GIP receptors in subcutaneous and oral formulations for obesity and metabolic conditions, alongside VK2809 for non-alcoholic fatty liver disease, VK0214 for X-linked adrenoleukodystrophy, and VK5211 for lean body mass recovery.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Viking Therapeutics Inc stock.

Our verdict on VKTX

Not valued: We cannot value this company yet.

ETFs with the most weight in VKTX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than VKTX in Biotechnology

129 more in this industry show a wider margin of safety.

Is VKTX undervalued or overvalued?

We do not publish a verdict on VKTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of VKTX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.